Venrock Healthcare Capital Partners II, L.P. 13D and 13G filings for Marinus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:07 pm Sale | 2022-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | Venrock Healthcare Capital Partners II, L.P. | 1,770,705 3.700% | -1,109,391 (-38.52%) | Filing |
| 2022-02-14 4:18 pm Purchase | 2021-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | Venrock Healthcare Capital Partners II, L.P. | 2,880,096 7.800% | 291,155 (+11.25%) | Filing |
| 2021-02-16 4:09 pm Purchase | 2020-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | Venrock Healthcare Capital Partners II, L.P. | 2,588,941 7.300% | 963,231 (+59.25%) | Filing |